Biosimilars

The biosimilar was approved for treating patients with age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.

The FDA recently approved Biologics' Yesafili as well as Samsung Bioepis and Biogen's Opuviz, both close copies of Regeneron Pharmaceutical’s Eylea. The approval offers ophthalmologists and patients additional therapeutic options.

The agency approved Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis, Biogen) as biosimilars to Eylea (Regeneron Pharmaceuticals).

In an annual report, the company revealed the impact of a dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability.

Two retina specialists participated in an Ophthalmology Times case-based roundtable discussion and shared their experiences using the anti-VEGF biosimilars, ranibizumab-eqrn and ranibizumab-nuna to manage retinal diseases.

According to the companies, the deal also includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams. Coherus will now focus on its oncology business.

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab).

ABP 938 is an investigational biosimilar to EYLEA® (aflibercept).

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

Samsung Bioepsis' SB15 was comparable to Eylea (aflibercept) in a 56-week randomized clinical trial that included a rerandomization at 32 weeks. The rerandomization resulted in 111 study volunteers switching from Eylea to the biosimilar for the last part of the study.

This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

SB15 (Samsung Bioepis) has shown similar efficacy, pharmacokinetics, safety, immunogenicity to aflibercept after 56 Weeks in phase 3 clinical trial.

Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have.

The 2023 Harrington Prize for Innovation in Medicine recognizes Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their work in retinal gene therapy for genetic diseases.

The Cardinal Health study reveals provider perceptions of commercially available biosimilars and anticipated launches, which have the potential to increase equitable access to critical treatments.

The Alteogen Inc. subsidiary company provided an update on its ALT-L9 biosimilar to compete with EYLEA

The considerations for biosimilars in clinical practice are interesting and remain to be determined, according to George A. Williams, MD.

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

Specialists seek more information for use in the treatment of patients diagnosed with retinal diseases

Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.

Coherus plans to file a Biologics License Application for FYB203 later in 2023 in preparation for an anticipated 2025 launch.

Continued education and financial incentives will become essential if biosimilars are to become a mainstay in ophthalmological markets, according to a recent report.

Results from our recent poll indicate a mixed bag of responses from ophthalmologists.

Weigh in on this month's survey question. The poll will be open until December 16, 2022.

Baseline age, best-corrected visual acuity, and central subfield thickness play role in predicting the efficacy of both drugs.

Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.

This post-hoc analysis was performed to evaluate immunogenicity over the long term.